Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.64 |
| ▸ | HPGD | P15428 | 2/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | PRNP | P04156 | 1/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.64 |
| ▸ | SLC9A1 | P19634 | 3/20 | 0.46 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.45 |
| ▸ | CDC7 | O00311 | 2/20 | 0.43 |
| ▸ | DBF4 | Q9UBU7 | 2/20 | 0.43 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.43 |
| ▸ | CDK2 | P24941 | 1/20 | 0.43 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.42 |
| ▸ | CCNC | P24863 | 1/20 | 0.41 |
| ▸ | CDK8 | P49336 | 1/20 | 0.41 |
| ▸ | CHUK | O15111 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27605036 | 0.85 | ALDH1A1 (0.47) | ALDH1A1HPGDKDM4ELMNAPRNP | |
| SCHEMBL5735008 | 0.83 | ALDH1A1 (0.65) | ALDH1A1HPGDKDM4EPDE4B | |
| Hydrochloric Acid SCHEMBL5542925 | 0.81 | ALDH1A1 (0.62) | ALDH1A1HPGDKDM4EPDE4B | |
| SCHEMBL14395763 | 0.81 | ALDH1A1 (0.44) | ALDH1A1HPGDKDM4ELMNAPRNP | |
| SCHEMBL4252554 | 0.81 | ALDH1A1 (0.44) | ALDH1A1HPGDKDM4ELMNAPRNP | |
| SCHEMBL4163540 | 0.81 | ALDH1A1 (0.68) | ALDH1A1HPGDKDM4ELMNAPRNP | |
| SCHEMBL3420262 | 0.80 | CYP2A6 (0.54) | ALDH1A1HPGDKDM4ELMNAPRNP | |
| SCHEMBL2031645 | 0.79 | ALDH1A1 (0.71) | ALDH1A1HPGDKDM4ELMNAPRNP | |
| SCHEMBL5735703 | 0.79 | ABL1 (0.52) | ALDH1A1HPGDKDM4EHSD17B10HSD17B1 | |
| SCHEMBL12885825 | 0.78 | ALDH1A1 (0.69) | ALDH1A1HPGDKDM4ELMNAPRNP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100345847-C | Novel biarylcarboxamides | ASTRAZENECA AB (SE) | 2007-10-31 | — | — | CN | claimed |
| CN-1400973-A | Novel biarylcarboxamides | ASTRAZENECA AB (SE) | 2003-03-05 | — | — | CN | claimed |
| EP-4646263-A1 | SPRK1 INHIBITORS AND METHODS OF USE | Allianthera (Suzhou) Biopharmaceutical Co., Ltd. (CN) | 2025-11-12 | — | — | EP | disclosed |
| US-12325704-B2 | SRPK1 inhibitors | EXONATE LIMITED (GB) | 2025-06-10 | — | — | US | disclosed |
| WO-2024155864-A1 | SPRK1 INHIBITORS AND METHODS OF USE | ALLIANTHERA (SUZHOU) BIOPHARMACEUTICAL CO., LTD. (CN) | 2024-07-25 | — | — | WO | disclosed |
| CN-111448193-B | SRPK1 inhibitors | 埃克森纳特有限公司 | 2023-12-22 | — | — | CN | disclosed |
| CN-108738319-B | Compounds for anti-angiogenic therapy or prophylaxis | 埃克森纳特有限公司 | 2023-09-29 | — | — | CN | disclosed |
| US-20220389015-A1 | SRPK1 INHIBITORS | EXONATE LIMITED (GB) | 2022-12-08 | — | — | US | disclosed |
| US-11420969-B2 | SRPK1 inhibitors | EXONATE LIMITED (GB) | 2022-08-23 | — | — | US | disclosed |
| CN-100345847-C | Novel biarylcarboxamides | ASTRAZENECA AB (SE) | 2007-10-31 | — | — | CN | disclosed |
| CN-1400973-A | Novel biarylcarboxamides | ASTRAZENECA AB (SE) | 2003-03-05 | — | — | CN | disclosed |
| US-20030008867-A1 | Compounds | ASTRAZENECA AB (SE) | 2003-01-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030008867-A1 | Compounds | DRD2, DRD1, GRIN2A | ALDH1A1 75/4885HPGD 1662/4885KDM4E 2318/4885 |
| US-11420969-B2 | SRPK1 inhibitors | SRPK1, SRPK3, SRPK2 | ALDH1A1 4429/4885HPGD 3277/4885KDM4E 3360/4885 |
| US-20220389015-A1 | SRPK1 INHIBITORS | SRPK1, SRPK3, SRPK2 | ALDH1A1 4429/4885HPGD 3277/4885KDM4E 3360/4885 |
| US-12325704-B2 | SRPK1 inhibitors | SRPK1, SRPK3, SRPK2 | ALDH1A1 4429/4885HPGD 3277/4885KDM4E 3360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.